[{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"MDL-101","moa":"Laminin alpha-1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Modalis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"MDL-101","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Modalis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"MDL-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Modalis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Modalis Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for MDL-101

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : MDL-101 is an experimental, epigenetic editing therapy, which is under investigation in the early-stage clinical trial studies for the treatment of LAMA2-congenital muscular dystrophy.

                          Brand Name : MDL-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : MDL-101

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : MDL-101 is an experimental, epigenetic editing therapy, which is under investigation in the early-stage clinical trial studies for the treatment of LAMA2-congenital muscular dystrophy.

                          Brand Name : MDL-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 07, 2024

                          Lead Product(s) : MDL-101

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : MDL-101, an experimental, epigenetic modulation therapy, in preclinical data it supported durability and efficacy of a differentiated precision medicine approached for Congenital Muscular Dystrophy type 1a.

                          Brand Name : MDL-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          April 20, 2022

                          Lead Product(s) : MDL-101

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank